Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study

References

• Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141:1537–1541.
   PubMed Web of Science ®Google Scholar
• Lebwohl M. Psoriasis. Lancet. 2003;361:1197–1204.
   PubMed Web of Science ®Google Scholar
• Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–139.
   PubMed Web of Science ®Google Scholar
• Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis. 1998;61(2 Suppl):11–21.
   PubMedGoogle Scholar
• Lebwohl M. Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. J Am Acad Dermatol. 2000;43(2 Pt 3):S43–SS6.
   PubMedGoogle Scholar
• Wollina U, Stander K, Barta U. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis–short- and long-term toxicity in 104 patients. Clin Rheumatol. 2001;20:406–410.
   PubMed Web of Science ®Google Scholar
• Grossman RM, Chevret S, Abi-Rached J, et al. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol. 1996;132:623–629.
   PubMedGoogle Scholar
• Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627–1632.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–2022.
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304–1312.
   PubMed Web of Science ®Google Scholar
• Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009;219:209–218.
   PubMed Web of Science ®Google Scholar
• Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56:31; e1–15.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534–542.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–1374.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598–606.
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558–566.
   PubMed Web of Science ®Google Scholar
• Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005;153:1192–1199.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Kimball AB, Krueger GG, et al. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol. 2005;53:887–889.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005;152:954–960.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006;154:1161–1168.
   PubMed Web of Science ®Google Scholar
• Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology. 2003;206:307–315.
   PubMed Web of Science ®Google Scholar
• Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat. 2007;18:25–31.
   PubMed Web of Science ®Google Scholar
• Brunasso AM, Puntoni M, Salvini C, et al. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: a study of 103 Italian patients. Acta Derm Venereol. 2011;91:44–49.
   PubMed Web of Science ®Google Scholar
• Saccomani C, Penz S, Guerre-Schmidt R, et al. Biological therapy for psoriasis: practical experience at a French dermatology unit. Ann Dermatol Venereol. 2009;136:877–882.
   PubMed Web of Science ®Google Scholar
• Berends MA, Driessen RJ, Langewouters AM, et al. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. J Dermatol Treat. 2007;18:76–83.
   PubMed Web of Science ®Google Scholar
• de Groot M, Appelman M, Spuls PI, et al. Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol. 2006;155:808–814.
   PubMedGoogle Scholar
• Mazzotta A, Esposito M, Costanzo A, Chimenti S. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Am J Clin Dermatol. 2009;10:319–324.
   PubMed Web of Science ®Google Scholar
• Antoniou C, Stefanaki I, Stratigos A, et al. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre. Br J Dermatol. 2010;162:1117–1123.
   PubMedGoogle Scholar
• Warren RB, Brown BC, Lavery D, et al. Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol. 2009;160:162–169.
   PubMed Web of Science ®Google Scholar
• Warren RB, Brown BC, Lavery D, Griffiths CE. Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre. Br J Dermatol. 2010;163:859–862.
   PubMed Web of Science ®Google Scholar
• Anderson P, Benford M, Harris N, et al. Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand. Curr Med Res Opin. 2008;3063–3072.
   PubMedGoogle Scholar
• ESOMAR. Professional Standards. 2011. Available from http://www.esomar.org/index.php/professional-standards.html. Cited 27 Jan 2011.
   Google Scholar
• US Department of Health and Human Services – National Institutes of Health. Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. 2007. Available from http://privacyruleandresearch.nih.gov/default.asp. Cited 27 Jan 2011.
   Google Scholar
• British Standards Institute. Data Protection Act 1998. 1998. Available from http://www.legislation.gov.uk/ukpga/1998/29/contents. Cited 27 Jan 2011.
   Google Scholar
• The Market Research Society (MRS) Census and Geodemographics Group. Geodemographics Knowledge Base. 2011. Available from http://www.geodemographics.org.uk/index.html?SESSID=jc7s9fc1etfchnb5ckj8of1b20. Cited 27 Jan 2011.
   Google Scholar
• Barker J, Hoffmann M, Guillet G, et al. Infliximab Demonstrates Early and Sustained Superiority to Methotrexate in the Treatment of Moderate to Severe Plaque-Type Psoriasis: the RESTORE I Trial. Presented at: 18th Congress of the European Academy of Dermatology and Venereology; 7–11 October 2009; Berlin, Germany.
   Google Scholar
• Christophers E, Barker JN, Griffiths CE, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24:548–554.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Stafford-Brady F, Chang CH, et al. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17:809–812.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol. 2006;33:712–721.
   PubMed Web of Science ®Google Scholar
• Gordon K, Korman N, Frankel E, et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. J Am Acad Dermatol. 2006;54(3 Suppl 2):S101–SS11.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004–2013.
   PubMed Web of Science ®Google Scholar
• Dauden E, Griffiths CE, Ortonne JP, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol. 2009;23:1374–1382.
   PubMed Web of Science ®Google Scholar